1. In Vivo

Direct To Consumer Approach Underscores Femtech’s Disruptive Potential

New Accelerator Looks To Fill Information Gaps About Femtech Market And Support Start-Ups

 
• By Lucie Ellis-Taitt

A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.

lightbulbs

The first of its kind in Europe, FemTech Lab launched in London at the end of 2020 as a new accelerator to help femtech entrepreneurs get their companies investment ready. It offers a 3-month program – enrolling 10 start-ups in the first cohort – to assist new companies in getting their products to market. During the program, the start-ups have access to world-class experts and resources to scale their product development, they can utilize relevant go-to-market channels, and receive advice on how to raise the necessary funds to get from innovative idea to fully fledged company.

Alongside business growth, FemTech Lab helps start-up founders to grow as leaders – addressing a talent gap in the European ecosystem

More from Leadership

The pre|CISION Approach: How Avacta Is Making Toxic Cancer Drugs Safe And More Effective

 
• By Jo Shorthouse

Avacta's approach to drug delivery is showing how 'masked' chemotherapy can dramatically improve safety profiles while maintaining or enhancing efficacy where it matters most.

Califf In Conversation: “Decimated” FDA Teams Endanger Biologics Progress

 
• By Barnaby Pickering

In Vivo spoke to the previous commissioner of the US FDA about recent ongoings at the agency, and where he believes policy should be directed for patient and industry benefit.

Rising Leaders 2025: Rob Barrow On Leading MindMed’s Psychedelic Renaissance

 
• By Jo Shorthouse

Rob Barrow's unconventional journey from finance to leading MindMed highlights his innovative approach to psychedelic medicine, aiming to transform mental health treatment with groundbreaking therapies.

UCB’s Alistair Henry On How AI Is Reshaping Biopharma Talent

 
• By Jo Shorthouse

Artificial intelligence is shaping many facets of the drug development and commercialization continuum. The need for computational skills within drug R&D is also changing what companies are looking for in young talent that is capable of both bridge biological expertise with computational literacy.

More from In Vivo